Moberg Pharma AB, of Stockholm, said it plans a bond issue, in part, to finance accretive acquisitions that will strengthen platforms for its strategic brands in the U.S. and allow for additional brands, increase international distribution and prepare for initiation of phase III studies for MOB-015, a topical formulation to treat nail fungus.